trending Market Intelligence /marketintelligence/en/news-insights/trending/0z17lo9owxwdkysy-h4t-q2 content esgSubNav
In This List

Cytosorbents gets EU approval to expand use of blood purification technology

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Cytosorbents gets EU approval to expand use of blood purification technology

Cytosorbents Corp. received European Union regulatory approval to expand the use of its CytoSorb blood purification technology to reduce high levels of bilirubin and myoglobin from the blood.

High levels of bilirubin, a bile pigment, are frequently associated with chronic liver disease and liver failure. Elevated myoglobin, a protein found in heart tissue and other muscles, is associated with accidents and traumatic injury.

The device is approved in the EU with distribution in 45 countries globally for extracorporeal cytokine adsorber that could otherwise cause massive inflammation, organ failure and death in common critical illnesses.